Document:

<PAGE>

                                                                    EXHIBIT 10.6

                     MARKETING AND DISTRIBUTORSHIP AGREEMENT

This Agreement made on October, 25, 2004             , by and between DIAMED
Medizintechnik GmbH, a corporation organized and existing under the laws of
Germany, with its principal place of business at Stadtwaldgortel 77, 50935 Koln,
Germany (hereafter referred to as "DIAMED") and OCCULOGIX INC., a corporation
organized and existing under the laws of the State of Delaware, the United
States of America, with its principal place of business at 5380 Solar Drive,
Suite 100, Mississauga, Ontario, Canada, L4W 5M8 (hereinafter referred to as
"OCCULOGIX"):

                                   WITNESSETH

WHEREAS, DIAMED desires to sell and market the PRODUCT (hereinafter defined) and
grant to OCCULOGIX certain distributor rights with respect to the PRODUCT in the
TERRITORY (hereinafter defined); and

WHEREAS OCCULOGIX is desirous of distributing the PRODUCT in the TERRITORY.

WHEREAS OCCULOGIX intends to purchase the PRODUCT from the MANUFACTURER which is
appointed by DIAMED for the production of the PRODUCT.

NOW, THEREFORE, for and in consideration of the mutual covenants and premises
hereinafter set forth, and other good and valuable consideration, the
sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:

ARTICLE 1: DEFINITIONS

As used in this Agreement, the following terms shall have the following meanings
respectively:

A:    "PRODUCT" shall mean the products set forth in the attached Exhibit A
      hereto.

B.    "MANUFACTURER" shall mean the producer nominated in the attached Exhibit A
      hereto.

C.    "TERRITORY" shall mean United States of America, Canada and Mexico and the
      Caribbean Islands.

D.    "TREATMENT DISEASE" shall mean hemo-rheological disorders in
      microcirculation.

E.    "FDA" shall mean the Federal Food and Drug Administration in the U.S..

F:    "TRADEMARKS" shall mean those listed in attached Exhibit B hereto.

                                        1

<PAGE>

ARTICLE 2: DISTRIBUTORSHIP

2.1   DIAMED hereby appoints OCCULOGIX as its exclusive distributor in the
      TERRITORY for the sale of PRODUCT solely to be used for the TREATMENT
      DISEASE, provided however, that OCCULOGIX obtains the FDA approval and
      other necessary approvals in the TERRITORY according to Article 4 of this
      Agreement. OCCULOGIX agrees to act as such exclusive distributor under the
      terms and conditions of this Agreement.

      In case that additional diseases should become available for treatment by
      the PRODUCT in the TERRITORY, OCCULOGIX shall have the right of first
      refusal under the provisions that OCCULOGIX obtains all necessary
      approvals as stipulated above.

2.2   This Agreement does not construe OCCULOGIX as the agent or legal
      representative of DIAMED for any purpose whatsoever. OCCULOGIX is not
      granted any right or authority to assume or to create any obligation or
      responsibility, expressed or implied, on behalf of or in the name of
      DIAMED or to bind DIAMED in any manner or thing whatsoever, or to accept
      any legal process to or intended for DIAMED.

2.3   OCCULOGIX shall not, directly or indirectly, seek customers for the
      PRODUCT or establish a branch or distribution depot related to the PRODUCT
      outside the TERRITORY.

2.4   OCCULOGIX shall not represent, market, nor sell any similar to or
      competitive PRODUCTs with PRODUCT during the term of this Agreement.

2.5   OCCULOGIX shall be solely responsible for all expenses and costs incurred
      in performing its duties hereunder, including, without limitation, all of
      its own operating and sales promotion expenses.

2.6   OCCULOGIX shall use its best efforts to promote the sale and use of, and
      to secure orders and develop the market for the PRODUCT in the TERRITORY.
      The business conducted by OCCULOGIX in connection with the marketing of
      the PRODUCT shall at all times be conducted and maintained so as not to
      detract from, interfere with or adversely reflect upon the goodwill and
      reputation of DIAMED, its TRADEMARKS and/or trade names and the PRODUCT.

2.7   OCCULOGIX also shall make its best efforts that public and private medical
      insurance reimbursement shall be applied for the TREATMENT DISEASE using
      the PRODUCT in the U.S.

ARTICLE 3: MINIMUM PURCHASE REQUIREMENT

                                       2

<PAGE>

3.1 From the date of concluding this Agreement until 5 (five)years after the
date of FDA approval of the PRODUCT, OCCULOGIX will purchase no less than 1000
(one-thousand) units of PRODUCT.

3.2   The minimum purchase quantities from the sixth year on shall annually be
      mutually agreed by both parties acting reasonably and assessing market
      potential.

3.3   For the purpose of this Article, the PRODUCT shall be considered purchased
      when the PRODUCT has actually been delivered to OCCULOGIX.

ARTICLE 4: REGULATORY APPROVAL

4.1   OCCULOGIX shall be responsible, at its own costs and expenses, for
      obtaining and maintaining the FDA and all other applicable approvals and
      validations for the marketing, sales and use of PRODUCT for the TREATMENT
      DISEASE in each country of the TERRITORY under the name of DIAMED. The
      necessary FDA approvals must be obtained by the end of 2006. If the FDA
      approvals can not be obtained by such day and year, OCCULOGIX shall
      consult with DIAMED and attempt to reach a mutual acceptable resolution.
      Despite consultation, if both parties cannot find a mutual acceptable
      resolution, DIAMED may terminate this Agreement upon six (6) months prior
      written notice to OCCULOGIX.

4.2   OCCULOGIX shall inform DIAMED of the documentation which is necessary for
      the FDA approval related to PRODUCT. Upon OCCULOGIX's request, DIAMED
      shall make its best efforts to provide technical data of PRODUCT within
      DIAMED's capacity.

4.3   OCCULOGIX shall not be entitled to any compensation from DIAMED even when
      OCCULOGIX may not obtain the FDA approval, or any other approval, of
      PRODUCT.

4.4   OCCULOGIX shall endeavor to obtain, at its own expenses, the FDA approval
      and other necessary approvals in the TERRITORY of the accessories of the
      PRODUCT, such as Filters or Tubing Sets, which may be required for the
      TREATMENT DISEASE.

4.5   Without limiting any other provision in the Agreement, OCCULOGIX shall
      fully comply with the FDA's Medical Device Reporting (hereinafter referred
      to as M.D.R.") regulation and with the S.O.P.

ARTICLE 5: FIRST REFUSAL RIGHT

5.1   In the event, that DIAMED develops improved PRODUCTs which may replace the
      existing PRODUCT, OCCULOGIX -will have the first refusal right to obtain
      the distribution rights of such improved PRODUCT of PRODUCT solely used
      for the TREATMENT DISEASE in the TERRITORY under the terms and conditions
      by mutual consent; provided, however, that OCCULOGIX shall, at its own
      costs and expenses, obtain all applicable approvals in the name of DIAMED
      of such

                                       3

<PAGE>

      PRODUCTs for the TREATMENT DISEASE in the TERRITORY within a reasonable
      period.

ARTICLE 6: TRADEMARK AND OTHER RIGHTS

6.1   OCCULOGIX shall be the exclusive licensee of the TRADEMARKS owned by
      DIAMED in the TERRITORY for use in association with the PRODUCT and shall
      use the TRADEMARKS without limitation, as instructed by DIAMED in
      distributing the PRODUCT purchased hereunder and shall not use any other
      TRADEMARKS in connection with such distribution without prior written
      consent of DIAMED. OCCULOGIX acknowledges that, as between DIAMED and
      OCCULOGIX, DIAMED is the owner of all rights, title and interest in and to
      the TRADEMARKS in the TERRITORY in any form or embodiment thereof and is
      the owner of the goodwill attached or which shall become attached to the
      TRADEMARKS in connection with the business and goods in relation to which
      the same has been, is or shall be used. Sales by OCCULOGIX shall be deemed
      to have been made by DIAMED for purposes of trademark registration and all
      uses of the TRADEMARKS by OCCULOGIX shall inure to the benefit of DIAMED.
      OCCULOGIX shall not, at any time, do or suffer to be done any act or thing
      which may in any way adversely affect any rights of DIAMED in and to the
      TRADEMARKS or any registrations thereof or which, directly or indirectly,
      may reduce the value of the TRADEMARKS or detract from its reputation. At
      DIAMED's request, OCCULOGIX shall execute any documents, including
      registered user agreements, reasonably required by DIAMED to confirm
      DIAMED's ownership of all rights in and to the TRADEMARKS in the TERRITORY
      and to confirm the respective rights of DIAMED and OCCULOGIX under this
      Agreement. OCCULOGIX shall not alter, obliterate, deface or remove any
      mark, marking, serial number or other symbol carried on the PRODUCT or on
      the packaging in which the PRODUCT are enclosed without the consent of
      DIAMED. In the event that DIAMED desires to change any such mark, marking,
      serial number or other symbol, OCCULOGIX will cooperate with DIAMED in
      such manner as may be agreed upon by the parties. OCCULOGIX never shall
      challenge DIAMED's ownership of or the validity of the TRADEMARKS or any
      application for registrations thereof, or any trademark registrations
      thereof, or any rights of DIAMED therein.

6.2   Should OCCULOGIX have already registered any of the TRADEMARKS prior to
      this agreement in its name or its predecessor's name, OCCULOGIX will take
      immediate action to change the ownership to DIAMED and inform DIAMED on
      such action without delay.

6.3   During the term of the Agreement and thereafter, OCCULOGIX shall not apply
      for or acquire the registration of the TRADEMARKS, nor shall OCCULOGIX
      contest DIAMED's right in or disturb DIAMED's use of the TRADEMARKS or
      goodwill therein. Should OCCULOGIX have the TRADEMARKS registered in its
      name of any other person, DIAMED shall have the right to have the
      registration cancelled or transferred to DIAMED.

6.4   In the event that OCCULOGIX learns of any infringement or imitation of the
      TRADEMARKS or of any use by any person of any trademark similar to the
      TRADEMARKS, it promptly shall notify DIAMED thereof. DIAMED thereupon
      shall

                                       4

<PAGE>

      take such action as it deems advisable for the protection of its rights in
      and to the TRADEMARKS and, if requested to do so by DIAMED. OCCULOGIX
      shall cooperate with DIAMED in all respects at DIAMED's sole expense. In
      no event, however, shall DIAMED be required to take any action if it deems
      it inadvisable to do so and OCCULQGIX shall have no right to take any
      action with respect to the TRADEMARKS without DIAMED's prior written
      approval.

6.5   Upon the termination of this Agreement for any reason whatsoever,
      OCCULOGIX shall, except as DIAMED may specifically authorize in writing,
      immediately cease and desist from carrying on any and all use of the
      TRADEMARKS, and shall immediately cease and desist from making any
      statements indicating, explicitly or implicitly, that it is an authorized
      DIAMED distributor or dealer of DIAMED's PRODUCTs or other DIAMED goods
      and services.

6.6   Any patent, design, copyright and other intellectual property rights
      embodied in the PRODUCT shall be the sole property of DIAMED or the third
      party designated by DIAMED; and OCCULOGIX shall not, either directly or
      indirectly, contest nor assist others in contesting the validity of such
      intellectual property rights. DIAMED shall be entitled to terminate this
      Agreement forthwith on notice to OCCULOGIX if OCCULOGIX should violate
      said obligation. OCCULOGIX shall not acquire any right in the PRODUCT by
      execution of this Agreement or performance hereunder or otherwise and
      shall not use any of them after termination of this Agreement resulting
      from expiration of its term or any other cause whatsoever.

6.7   Nothing in this Agreement shall be construed as a warranty or
      representation that the PRODUCT or the use thereof will be free from
      infringement of any patent or other intellectual property rights of any
      third party. DIAMED shall not be under any obligation to defend, or to
      participate in the defense of, OCCULOGIX against any claim or suit
      alleging such infringement; provided, however, that DIAMED shall, at
      OCCULOGIX's costs, cooperate and assist OCCULOGIX in the defense of any
      such claim or suit.

6.8   In the event that OCCULOGIX obtains any intellectual property right
      relating to the TREATMENT DISEASE using PRODUCT, DIAMED shall have the
      first refusal right to obtain a non-exclusive right and license from
      OCCULOGIX to use such intellectual property right for manufacture, sales
      and use of PRODUCT outside the TERRITORY for such territories where the
      PRODUCT is actively distributed during the term of this Agreement.

ARTICLE 7: PROMOTION AND ADVERTISEMENT

OCCULOGIX shall exert its best efforts in marketing, promoting and advertising
the PRODUCT at its own costs.

ARTICLE 8: INVENTORY

OCCULOGIX shall maintain sufficient stock of the PRODUCT for the purpose of
distribution at its own cost, and shall deliver the PRODUCT to its customers by
a "first in, first out" method.

                                       5

<PAGE>

ARTICLE 9: MANUFACTURER

      a)    The sole purpose of this agreement concerns the marketing and
            distribution rights for the PRODUCT.

      b)    DIAMED agrees for OCCULOGIX to enter into a manufacturing and supply
            agreement for the PRODUCT only with MANUFACTURER nominated by DIAMED
            provided that such MANUFACTURER meets the reasonable supply and
            quality demands of OCCULOGIX and which will incorporate all rights
            and obligations among OCCULOGIX and MANUFACTURER. In advance of
            this, DIAMED will conclude an agreement with MANUFACTURER to allow
            such manufacturing and supply agreement. DIAMED has the right to
            terminate such agreement and provide an alternative MANUFACTURER for
            OCCULOGIX to conclude a new agreement.

      c)    Occulogix has the right to request PRODUCT changes by MANUFACTURER
            at OCCULOGIX's expense. Any PRODUCT change however, must be approved
            by DIAMED in writing and in advance.

      d)    For the duration of this agreement, the rights on such PRODUCT
            changes are passed over to OCCULOGIX with validity for its TERRITORY
            only. Upon termination of the agreement, all such rights are to be
            transferred to DIAMED without compensation. The rights for all other
            territories pass over to DIAMED immediately when developed and
            without compensation.

ARTICLE 10: TECHNOLOGY DEVELOPMENT FEE:
      OCCULOGIX agrees that a development fee shall be paid by the Manufacturer
      to DIAMED.

ARTICLE 11: deleted

ARTICLE 12: CONFIDENTIALITY

During the term of this Agreement including any renewal under Article 15 and for
a period of five (5) years thereafter, or ten (15) years after the effective
data of this Agreement, whichever is longer, neither party hereto shall disclose
or otherwise divulge to any third party any confidential information which may
be acquired from the other in connection with the PRODUCT, this Agreement, or
its performance, except for any information which:

      a)    is known to the public or to the receiving party prior to
            disclosure;

      b)    is disclosed to the receiving party by a third party under no
            obligation of secrecy to the other party after disclosure, or

      c)    becomes known to the public through no fault of the receiving party
            after disclosures, or

      d)    is ordered to be disclosed by a court of law.

                                       6

<PAGE>

ARTICLE 13, FORCE MAJEURE

13.1  Neither party hereto shall be liable to the other in any manner for
      failure or delay in fulfilment of all or part of this Agreement, or any
      individual contract, which is directly or indirectly owing to any causes
      or circumstances beyond that party's control, including, but not limited
      to, acts of God, governmental orders or restriction, war, war-like
      conditions hostilities, sanctions, mobilization, blockade, embargo,
      detention, revolution, riot, looting, strike, lockout, plague or other
      epidemics, fire, earthquake, explosion, flood, and shortage of raw
      materials.

13.2  Notwithstanding the foregoing, no occurrence of an event of Force Majeure
      shall relieve OCCULOGIX of its obligation to make any payment hereunder.

ARTICLE 14, ASSIGNMENT

OCCULOGIX shall not assign, transfer or otherwise dispose of this Agreement,
voluntarily or by operation of law, in whole or in part, to any individual, firm
or corporation without the prior written consent of DIAMED.

ARTICLE 15, TERM

15.1  This agreement shall be effective from October 25, 2004 until ten (10)
      years after the date of FDA approval of PRODUCT for the TREATMENT DISEASE,
      unless terminated prior to such expiration date by either party, as
      provided herein, and shall automatically be extended for one (1) year term
      unless DIAMED or OCCULOGIX gives the other written notice of its intention
      to terminate this Agreement at least six (6) months prior to the
      expiration date of the term then in effect.

15.2  Notwithstanding the foregoing paragraph, the following paragraphs shall
      survive any expiration or termination of this Agreement: Article 6 and 12,
      Paragraph 16.2 and Article 20.

ARTICLE 16, TERMINATION

16.1  DIAMED may forthwith terminate this Agreement without any compensation to
      OCCULOGIX by giving a written notice of termination to OCCULOGIX if:

A. OCCULOGIX becomes insolvent or a petition in bankruptcy or for corporate
   reorganization or for any similar relief is filed by or against OCCULOGIX
   or a receiver is appointed with respect to any of the assets of OCCULOGIX,
   or liquidation proceeding is commenced by or against OCCULOGIX, or

B. the whole or an important part of the business of OCCULOGIX is transferred
   to a third party by agreement, order of court or otherwise, and such
   transfer adversely affects the sale of the PRODUCT in the TERRITORY
   pursuant to this Agreement, or

C. OCCULOGIX defaults in payment for any PRODUCT or any debt owing to DIAMED
   or otherwise defaults in relation to any of the provisions of this
   Agreement hereunder except for those in Paragraphs 2.3 and 2.4 and does
   not

                                       7

<PAGE>

   make the payment or remedy the default within thirty (30) days after a
   prior written notice is given requesting the payment or remedy of the
   default, or

D. any essential changes in the management personnel or ownership of the
   shares of OCCULOGIX would adversely affect the sale of the PRODUCT in the
   TERRITORY pursuant to this Agreement, or

E. OCCULOGIX violates the prohibition provided for in Paragraphs 2.3 and 2.4
   herefor and does not take reasonable steps to remedy the violation within
   thirty (30) days after a written notice is given evidencing such
   violation.

F. if the production agreement between OCCULOGIX and MANUFACTURER is
   terminated.

16.2  Termination of this Agreement pursuant to the preceding Paragraph shall be
      without prejudice and shall be additional to any right of DIAMED under
      this Agreement, law, statute or otherwise. Upon termination of this
      Agreement and/or such individual contracts for the PRODUCT, all payments
      to be made under this Agreement and/or such individual contracts in
      connection with the sale of the PRODUCT hereunder up to the date of
      termination shall become due.

16.3  If OCCULOGIX fails to fulfil the provisions and/or payments stipulated in
      the Paragraphs 3.1 and 3.2. DIAMED may, at its option, modify the
      exclusive right granted to OCCULOGIX hereunder to a non-exclusive right.

ARTICLE 17: GOVERNING LAW

This Agreement shall be governed by the laws of Germany, seat of court is Koln
(Cologne).

ARTICLE 18: NON-WAIVER

The waiver, express or implied, by either of the parties hereto of any right
hereunder or of any failure to perform or breach hereof by the other party
hereto shall not constitute or be deemed as a waiver of any other right
hereunder or of any other failure to perform or breach hereof by the other
party, whether of a similar or dissimilar nature.

ARTICLE 19: ENTIRETY

This Agreement and its Exhibit contain the entire agreement of the parties with
respect to the subject matter herein contained and supersedes any prior
Agreements or understandings between the parties except the S.O.P.

ARTICLE 20 ARBITRATION

All disputes, controversies or differences which may arise between the parties,
out of or in relation to or in connection with this Agreement, or for the breach
thereof, shall be settled by mutual consultation between the parties hereto in
good faith as promptly as possible, but failing an amicable settlement, shall be
finally settled by arbitration to be held in Koln (Cologne), Germany under the
Rules of Conciliation and

                                       8

<PAGE>

Arbitration of the International Chamber of Commerce, by which each party hereto
agree to be bound.

ARTICLE 21: NOTICE

21.1  Unless otherwise provided in this Agreement, all notices to be given
      hereunder shall be in writing and sent by registered airmail to the
      respective addresses of the parties stated above or to such other
      addresses as may be indicated in writing by the parties hereto by notice
      pursuant to this Paragraph. If either party has changed its address, a
      written notice thereof shall be given to the other party pursuant to this
      Paragraph.

21.2  All notices shall, be deemed to have been given on the day when such
      notice is mailed by registered airmail.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
by their respective duly authorized representatives as of the day and year first
above written.

/s/ ELIAS VAMVAKAS                         /s/ Hans K. Stock
------------------------------             -------------------------------------
OCCULOGIX CORPORATION                      DIAMED Medizintechnik GmbH
Date: October 25, 2004                         Hans K. Stock
                                               President
                                           Date: October 25, 2004

                                       9

<PAGE>

Exhibit A

      PRODUCT:

Product means a blood plasma treatment device including accessories and software
for use in the treatment of Treatment Diseases.

MANUFACTURER shall mean:

Mesys GmbH Medizinische Systeme
Beneckeallee 30
30419 Hannover
Germany
Fon: +49-511 67 99 99-0
Fax: +49-511 67 99 99-11
e-mail: mesys@aol.com

                                       10

<PAGE>

                                       11

<PAGE>

Exhibit B

TRADEMARKS shall mean the following DIAMED trademarks:

Octo Nova

Octo Therm

Cellsorbtion

AutoPrep

Octo

Angiopheresis

Immunapheresis

LipidNet

Diamed

                                       12<PAGE>
                      PATENT LICENSE AND ROYALTY AGREEMENT

     THIS AGREEMENT (the "Agreement") is made by and between OccuLogix, Inc.
(formerly Vascular Sciences Corporation), a Delaware Corporation (the
"Licensee"), and Prof. Dr. Richard Brunner ("Brunner") living in Germany and
listed as inventor along with Prof. Dr. Helmut Borberg ("Borberg") in US patent
application 09/000,917, which is the parent application of US letters patent
6,245,038 issued June 12, 2001 (the "Patent").

     WHEREAS, Borberg assigned all his right, title and interest to the Patent
and the Patent Rights to Dr. Hans Stock ("Stock");

     WHEREAS, Stock originally licensed any and all of his rights, title and
interests to the Patent and the Patent Rights to the Licensee in an undocumented
oral agreement;

     WHEREAS, Stock executed a patent license and royalty agreement with
Licensee as of August 6, 2004 and amended and restated that agreement as of the
date hereof;

     WHEREAS, Brunner executed a patent license and royalty agreement with a
predecessor of the Licensee as of May 6, 2002 and amended and restated that
agreement as of the date hereof;

     WHEREAS, Brunner continues to desire to license any and all of his rights,
title and interest to the Patent and the Patent Rights derived therefrom to
Licensee, and

     WHEREAS, Licensee continues to desire to obtain an exclusive license to all
of Brunner's interest in the Patent and the Patent Rights derived therefrom and
to exclusively own the License to any and all of his rights, title, interests
and ownership to the Patent and any and all related patents, rights and
inventions that specifically relate to the Patent whether owned now or at any
time in the future by Brunner (the "License"), and

     WHEREAS, Brunner shall be eligible to receive any and all consideration and
compensation from the Licensee, such as those pledged to be made by the Licensee
to Brunner under the terms of this Agreement.

     NOW THEREFORE, in consideration for guaranteed Advance Royalty Payments and
Royalty Payments as described below, and other good and valuable consideration,
the parties agree as follows:

1.   Patent Rights. Shall mean any and all of Brunner's rights, title, ownership
     and interests in and to US letters patent 6,245,038 and any and all
     inventions, modifications, continuations-in-part, extensions, divisions,
     improvements, etc. made by Brunner or his agents, in any and all areas that
     relate directly to the Patent, regardless of whether such inventions or
     improvements are patentable or may become patented; all inventions,
     modifications, continuations-in-part, extensions, divisions, improvements,
     etc. shall automatically be incorporated herein without the payment of any
     additional fees, royalties or any other compensation or considerations of
     any kind.

<PAGE>

                                     - 2 -

2.   License Grant. Brunner confirms that he has exclusively licensed, and does
     hereby continue to exclusively license, in accordance with the terms set
     forth below, unto Licensee, Brunner's entire undivided right, title,
     ownership and interest in and to the Patent and the Patent Rights,
     throughout the Territory, to be held and enjoyed by Licensee the same as it
     would have been held and enjoyed by Brunner if this Patent License and
     Royalty Agreement had not been made and entered into. The exclusive license
     granted herein also includes an exclusive right for the Licensee to grant
     expressly or implicitly, directly or through its subsidiaries or
     affiliates, sublicenses to the Patent and the Patent Rights without the
     requirement to pay any additional royalty fee or sublicense fee to Brunner,
     to end users of the patented method including medical practitioners and
     medical clinics.

     The exclusive license granted herein also includes an exclusive right for
     the Licensee to grant sublicenses to the Patent and the Patent Rights to
     unaffiliated third parties other than the end users referred to
     hereinbefore. The Licensee acknowledges that such sublicensee shall not
     have the right to grant sub-sublicenses to the Patent and the Patent Rights
     unless consented to in writing by Brunner; sub-sublicensing to end-users as
     defined in the paragraph above is, however, permitted without consent.

     Brunner recognizes that by signing this Agreement, the combination of this
     Agreement and a patent license and royalty agreement between Stock and
     Licensee will collectively constitute an EXCLUSIVE PATENT LICENSE AND
     ROYALTY AGREEMENT by which Brunner and Stock grant an exclusive license in
     the Patent to Licensee including the right to sue for past infringement.

3.   Representation by Brunner. Brunner warrants that he, along with Borberg, as
     the joint inventors of United States Patent 6,245,038, exclusively owns and
     possesses the Patent and the Patent Rights, and has all right and title
     thereto and that this Patent License and Royalty Agreement is made without
     encumbrance or threat of future interference by others claiming ownership
     therein and that no security interests to any third party exists therein or
     any other agreement to the contrary.

4.   Representation by Licensee. Licensee represents that it is a bona fide
     corporation in good standing in Delaware.

5.   Advance Royalty Payments. Licensee agrees to pay Brunner Fifty Thousand
     Dollars ($50,000 USD) annually as an advance and credited against any and
     all Royalty Payments paid in accordance with this Agreement. Such Advance
     Royalty Payments shall be non-refundable and be paid to Brunner and in
     equal payments of Twelve Thousand Five-hundred Dollars ($12,500 USD), made
     quarterly, on or before the expiration of Forty-five (45) days after the
     reporting close of each prior calendar quarter.

6.   Royalty Payments. Licensee agrees to pay royalties to Brunner totaling One-
     Half Percent (0.5% in USD). Royalty Payments shall be non-refundable and be
     calculated and paid based upon Total Net Revenues that Licensee, or any
     subsidiary of licensee or any company affiliated with licensee receives
     from the bona fide commercial sales of its

<PAGE>
                                     - 3 -

     Products sold in reliance and dependence upon the validity of the Patent's
     claims and of the Patent Rights in the Territory.

7.   Sublicense Fee. In instances where Brunner has consented to a sublicense to
     the Patent and the Patent Rights from Licensee to a third party who is not
     an end user of the patented method, Licensee agrees to pay to Brunner a
     sublicense fee constituting a non-refundable cash payment equal to
     Twelve-and-a-Half Percent (12,5% in USD) of any:

     (i)   Upfront cash payment made to Licensee in consideration of the
           sublicense;

     (ii)  Sublicense fees received by Licensee in consideration of the
           sublicense;

     (iii) Premium over the fair market value of equity investments in Licensee
           in consideration of the sublicense; and

     (iv)  Non-cash consideration received by Licensee from a sublicense in
           consideration of the sublicense, such consideration to include,
           without limitation, equity in other companies and the value of any
           license granted to Licensee.

8.   Accounting and Timing of Royalty Payments and of payments of Sublicense
     Fees. Upon making each Royalty and Sublicense Fee Payment, Licensee shall
     provide Brunner with a summary of the accounting used to determine the
     amount of Royalty Payment and Sublicense Fees due. Royalty Payments and
     Payments of Sublicense Fees shall be made by wire transfer and shall be
     computed on Total Net Revenues received by the Licensee by the reporting
     close of each calendar quarter and distributed and paid to Brunner and on a
     quarterly basis, on or before the expiration of Forty-five (45) days after
     the reporting close of each prior calendar quarter.

9.   Failure to Pay by Licensee. Should Licensee fail to make any payments as
     required herein, and should the Licensee fail to cure the breach created
     thereby, any and all rights, title and ownership to the License provided to
     the Licensee under this Agreement shall be forfeited and any and all such
     rights, title and ownership to the License shall, upon notice of the
     failure to cure the breach, immediately revert to Brunner, and all monies
     paid by Licensee until such date shall be retained by him without
     forfeiture.

10.  Territory. Shall mean the United States and any other jurisdictions subject
     to recognizing any valid claims of the Patent or of the Patent Rights.

11.  Total Net Revenues. Shall mean total gross revenues less any discounts,
     rebates, shipping costs, handling costs, transportation insurance costs,
     importation fees, and duties on any and all Products sold by the Licensee
     in the Territory which are sold in reliance upon and which are specifically
     used for extracorporeal therapies for the treatment of ophthalmic diseases
     in accordance with or subject to any of the valid claims of the Patent. In
     the case of sales of filters for ophthalmic treatment within the meaning of
     the Patent, either directly by Licensee or through Licensee's subsidiaries
     or a company affiliated with Licensee, such total gross revenues shall be
     deemed to be the cost of the filters to

<PAGE>
                                     - 4 -

     Licensee; or in case of Products having components in addition to said
     filters, the allocated cost of the filters to Licensee relative to the
     total costs of said Products. For other Products the Total Net Revenues
     shall be the actual sales price to purchasers of the Products, less any of
     the discounts etc. as mentioned above.

12.  Records. Licensee agrees to keep complete and correct books, accounts and
     records according to Generally Accepted Accounting Principles (GAAP)
     regulations to facilitate computation of Royalty Payments and Sublicense
     Fees. Brunner or his representatives acceptable to Licensee, shall have a
     full right of accounting including the right to confidentially examine
     Licensee's books and records, at all reasonable times and upon reasonable
     notice, for the purpose of verifying the amount of Royalty Payments due. In
     case of miscalculations elicited by such examination, Licensee shall
     compensate Brunner for the agreed upon shortfall within thirty (30) days of
     receipt of a detailed report outlining the Royalty Payments determined to
     be due. In case the shortfall exceeds 5% or US$ 5.000, whichever is
     greater, Licensee shall reimburse Brunner's costs for the examination.

13.  Products. Shall mean any filters, tubing sets or pumps sold by Licensee or
     its subsidiaries or affiliates to unaffiliated third parties in the
     Territory for the purposes of providing extracorporeal therapies for the
     treatment of the ophthalmic diseases as defined by any valid claim(s) of
     the Patent.

14.  Term and Termination. The Royalty Payments shall be due to Brunner
     beginning with the first bona fide commercial sale of any Product in the
     Territory and may, at the discretion of Licensee terminate upon the first
     of any of the following three events to occur: (a) all patents of the
     Patent Rights expire; (b) all material patent claims of the Patent Rights
     are determined, in the opinion of an experienced patent attorney approved
     by Brunner and Licensee or an independent experienced patent attorney
     selected by the American Arbitration Association in accordance with its
     rules if such joint approval cannot be obtained after thirty (30) days, to
     be invalid or unenforceable; or (c) a similarly fashioned competitive
     extracorporeal product, method or technology is commercially introduced in
     the Territory for use in ophthalmic indications that could not be deterred
     by best-efforts enforcement/infringement proceedings brought by Licensee
     against the competitive product, method or technology where such
     proceedings are made in reliance in full or in part upon the Patent's
     claims and or the Patent Rights.

     "material patent claims" within the meaning of this section of the
     Agreement are those claims of the Patent Rights covering a method for the
     effective therapeutic treatment of Age-related Macular Degeneration (AMD)
     using plasma differential separation techniques.

     Either Party may terminate this Agreement in the event of a material breach
     by the other Party that is not addressed elsewhere in this Agreement,
     provided only if the breaching Party is given Notice of the breach and a
     reasonable time, not to exceed thirty (30) days from the date of receipt of
     such Notice, in which to cure such breach. Brunner may further terminate
     this Agreement in case of a final court order of bankruptcy or insolvency
     of Licensee, and in case Licensee refuses to defend and/or enforce the
     Patent

<PAGE>
                                     - 5 -

     (which defence or enforcement may include a license or other reasonable
     settlement) as provided under section 15. In the case of bankruptcy or
     insolvency of Brunner the Licensee shall retain its rights to the Patent
     and the Patent Rights in accordance with the terms of this agreement.

     The right of Brunner to receive the royalty payments and Sublicense Fees
     under sections 5, 6 and 7 shall survive the death of Brunner and shall
     become a receivable of Brunner's estate until the termination of this
     agreement.

15.  Patent Defense. Licensee shall pay for any and all costs incurred for
     patent maintenance, enforcement and defense of the Patent or the Patent
     Rights in the Territory other than re-examination costs as noted below.
     Brunner may, at his own expense, join with the Licensee in the enforcement
     or the defense of the Patent or the Patent Rights in the Territory. In case
     Licensee, after due consideration expressly indicates its refusal in
     writing to Brunner to enforce or defend the Patent or the Patent Rights in
     the Territory then Brunner may take his own steps to enforce or defend the
     Patent at his own expense. Brunner has no obligation for such
     participation, defense or enforcement at own expenses. Licensee may deduct
     the allocated costs for one reexamination procedure of US letters patent
     6,245,038 incurred under this section 14 from future Royalty Payments and
     Sublicense Fees payable to Brunner under sections 6 and 7.

16.  Participation. Brunner agrees, in consideration of the premises herein,
     that his executors and administrators will, at any time upon request,
     communicate to the Licensee, its successors and assigns, any facts relating
     to said Patent and Patent Rights, and the history thereof, known to him or
     his successors and assigns, and that he will testify as to the same in any
     interference or other proceeding when requested to do so by the Licensee,
     its successors and assigns. Any and all costs of such participation by
     Brunner or his successors and assigns shall be borne by Licensee.

17.  Succession. Brunner binds himself and his heirs, executors, administrators,
     employees and legal representatives, as the case may be, to execute and
     deliver to the Licensee, any further documents or instruments and to do any
     and all further acts that may be deemed necessary by the Licensee (i) in
     connection with any aspect of the re-examination proceedings, (ii) in
     connection with any proceedings to enforce or defend the Patent; (iii) to
     file applications for improvements and inventions in any country where
     Licensee may elect to file such application(s), and (iv) that may be
     necessary to vest in the Licensee, the license, rights or title herein
     conveyed, or intended so to be, and to enable such title to be recorded in
     the United States and or foreign countries where such application(s) may be
     filed. Any and all costs of such participation by Brunner or his successors
     and assigns shall be borne by Licensee.

18.  Relationship of the Parties: Indemnification. It is agreed that this
     Agreement does not make any Party herein a general or special agent, legal
     representative, subsidiary, joint venturer, partner, employee or servant of
     any other Party herein for any purpose.

19.  Validity. During the time of this agreement, licensee will not challenge
     the validity of the patent rights at court or with patent authorities, or
     will support third parties in such a

<PAGE>
                                     - 6 -

     challenge. The parties acknowledge that the re-examination proceedings
     shall not be considered a challenge of the Patent Rights.

20.  Breach and Disputes. Any breaching Party shall have Thirty (30) Days from
     the date of notification to cure such breach. Any dispute between the
     Parties to this Agreement shall be resolved through binding arbitration,
     which shall be governed under the rules and regulations of the American
     Arbitration Association.

21.  Forum, Venue and Governing Law. This agreement shall be governed and
     interpreted under Delaware law (without applying its conflict of law
     principles). Exclusive venue for legal proceedings arising hereunder shall
     be in New York, New York.

22.  Entire Agreement. This Agreement supersedes any prior understanding that
     may have been reached between the Parties and encompasses the entire
     agreement between the Licensee and Brunner with respect to the Patent and
     the Patent Rights. The terms of this Agreement are confidential and shall
     be maintained by the Parties in accordance thereby.

23.  Modification. This Agreement cannot be modified except in writing executed
     mutually between the Parties.

24.  Assignment. Licensee shall not grant, transfer, convey or otherwise assign
     any of its rights under this Agreement without the express consent in
     writing of Brunner.

     IN WITNESS WHEREOF, the Parties have signed and executed this Agreement and
have caused this Agreement to become effective as of the Effective Date last
executed below.

OCCULOGIX, INC.                            Prof. Dr. RICHARD BRUNNER

By: /s/ Elias Vamvakas                     By: /s/ Richard Brunner
   ------------------------------             --------------------------------
Title: Chief Executive Officer
Date:  October 25, 2004                    Date: October 25, 2004

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}]]